Fresenius Medical Care AG (NYSE:FMS) Shares Sold by Lodestar Private Asset Management LLC

Lodestar Private Asset Management LLC lessened its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 4.6% in the third quarter, HoldingsChannel reports. The fund owned 14,407 shares of the company’s stock after selling 700 shares during the period. Lodestar Private Asset Management LLC’s holdings in Fresenius Medical Care were worth $307,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allworth Financial LP boosted its holdings in shares of Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after acquiring an additional 581 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after purchasing an additional 1,675 shares during the period. ORG Wealth Partners LLC acquired a new position in shares of Fresenius Medical Care during the 3rd quarter valued at $112,000. ORG Partners LLC bought a new stake in shares of Fresenius Medical Care in the 1st quarter worth $110,000. Finally, SageView Advisory Group LLC acquired a new stake in shares of Fresenius Medical Care in the first quarter valued at $127,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Trading Down 2.3 %

Shares of NYSE FMS opened at $20.39 on Wednesday. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. Fresenius Medical Care AG has a 12 month low of $16.46 and a 12 month high of $22.76. The company has a market cap of $11.97 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 1.11 and a beta of 0.91. The business has a fifty day simple moving average of $20.31 and a 200-day simple moving average of $20.18.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting the consensus estimate of $0.38. The company had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Sell-side analysts predict that Fresenius Medical Care AG will post 1.52 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on FMS shares. StockNews.com began coverage on shares of Fresenius Medical Care in a research report on Tuesday, October 8th. They issued a “strong-buy” rating on the stock. Truist Financial increased their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Fresenius Medical Care currently has an average rating of “Hold” and an average target price of $23.00.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.